Involvement of diazepam-insensitive benzodiazepine receptors in the suppression of DOI-induced head-twitch responses in diabetic mice

Abstract

We suggest that the abnormal diazepam-insensitive benzodiazepine receptor function partly underlies the suppression of DOI-HTRs in diabetic mice.

Head‐twitch response in rodents induced by the hallucinogen 2,5‐dimethoxy‐4‐iodoamphetamine: a comprehensive history, a re‐evaluation of mechanisms, and its utility as a model

“…[137] GABA Several allosteric modulators of the GABA A receptor have been examined for their influence on the DOI HTR. Both the high efficacy benzodiazepine agonist diazepam and the inverse agonist flumazenil appear to have no influence on DOI-elicited HTRs, [67,86,120,138] while the partial inverse agonist Ro154513 attenuates the DOI-induced HTR. [67,138] Furthermore, the direct GABA A agonist bicuculline attenuates DOI-induced head twitches.…”

“…[67,138] Furthermore, the direct GABA A agonist bicuculline attenuates DOI-induced head twitches. [138] More comprehensive studies directly comparing a range of compounds with various pharmacological actions at this receptor will help elucidate the potential modulatory role of GABA A receptors. A single paper has examined the role of metabotropic GABA B receptors in DOI's behavioural effects.…”

“…Both the high efficacy benzodiazepine agonist diazepam and the inverse agonist flumazenil appear to have no influence on DOI-elicited HTRs, [67,86,120,138] while the partial inverse agonist Ro154513 attenuates the DOI-induced HTR. [67,138] Furthermore, the direct GABA A agonist bicuculline attenuates DOI-induced head twitches. [138] More comprehensive studies directly comparing a range of compounds with various pharmacological actions at this receptor will help elucidate the potential modulatory role of GABA A receptors.…”

“…Sprague-Dawley 1.25-3.0, NR 5-9 [114,32,131,66] Listar 1.0, (AE) 8 [113] OFA S-D 1.0-3.0, (AE) 5-7 [120] Mouse SAMP6 1.0, NR 83 [78] DBA-2J 1.0, (AE) 7 0 [65] C57Bl/6J (background) 1.0,1.5, (AE) 48,68 [119,121] C57Bl/6J 1.0, (+) 46 [76] C57Bl/6J 1.0, (AE) 30,40 [48,65] CAST/Ei 1.0, (+) 44 [76] SAMR1 1.0, NR 33 [78] 129S6/SvEv 2.0, NR 32 [94] Aston MF1 0.5, (AE) 3 2 [153] ICR 1.0, (AE) 28,29 [67,138] ICR 1.0, NR 25,26 [68,154] C3HeB/FeJ 1.0, (+) 28 [76] Aston MF1 1.0, NR 27 [141] 129Sv 2.0, NR 21 [194] C57Bl/6N 1.0, NR 19 [74] Balb/cJ 1.0, (+) 18 [76] NIH Swiss 1.0, (-) 18 [73] CBA 2.5, NR 16 [87] Swiss Webster 1.0, (-) 15 [73] Albino ICR 1.0, (AE) 20,25 [61,146] Albino ICR 1.25-2.5, (AE) 8,15 [4,56] Albino ICR 2.5, (-) 15 [56] Albino ICR 1.0, NR 8,9 [140,252] Albino ICR 2.5, (+) 8 [56] A/J 1.0, (+) 9 [76] NMRI 1.0, (AE) 8 [236] Dosing issues: problem of non-selectivity…”